Advertisement

Gilead in talks to expand global supply of COVID-19 drug remdesivir

Follow The Hawk on Google News+ Follow

Advertisement


Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.

The drugmaker did not disclose details about the companies.

Advertisement

With several countries across the globe reeling from the coronavirus outbreak, interest in remdesivir has been high as there are currently no approved treatments or vaccines for COVID-19, the respiratory illness caused by the new coronavirus.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Gilead last week received the U.S. Food and Drug Administration's emergency use authorization for using remdesivir as a treatment against COVID-19, after the drugmaker provided data showing the drug had helped COVID-19 patients.

Gilead also said on Tuesday it was negotiating long-term licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries and that it would provide technology to aid the production.

Advertisement

One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, will start remdesivir production this month, Reuters reported on Tuesday, citing a senior company executive.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

Remdesivir was previously available only for patients enrolled in clinical trials or those cleared to get the drug under expanded use and compassionate use programs.

Gilead, which has already said it will donate the first 1.5 million doses of remdesivir, also previously said it was focused on making the drug accessible and affordable to as many people as possible upon approval.

Gilead said it was working to build a consortium of manufacturing partners to help maximize global supply of the drug, which requires scarce raw materials and specialized manufacturing capabilities with limited global capacity.

The company also said it was in advanced talks with UNICEF to deliver remdesivir using the agency's distribution networks.

—Reuters

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST